NeOnc’s Patent Portfolio and Nose-to-Brain Delivery Tech Could Expand Beyond Single Drug — NeOnc Technologies Holdings, Inc.

Event summary

NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for NEO100, showing a 48.9% six-month progression-free survival rate in recurrent IDH1-mutant high-grade glioma.
The company holds a patent portfolio of 28 issued and 14 pending U.S. patents, plus 65 issued and 28 pending internationally, covering intranasal delivery technology.
Preclinical evidence suggests NEO100 could facilitate delivery of other pharmaceuticals along the nose-to-brain pathway.
NeOnc plans to request a Type B FDA meeting to align on a registrational development path for NEO100.

The big picture

NeOnc’s Phase 2a results for NEO100 highlight the potential of its intranasal delivery technology to overcome the blood-brain barrier, a significant challenge in CNS drug development. The company’s extensive patent portfolio suggests a broader platform strategy that could extend beyond oncology into neurological diseases. If successful, this could reposition NTHI as more than a one-drug biotech, potentially attracting investors looking for scalable biotechnology platforms.

What we're watching

Platform Expansion: Whether NeOnc can validate its intranasal delivery technology for additional CNS therapies beyond NEO100.
Regulatory Pathway: The pace at which the FDA will agree to a pivotal design for NEO100’s registrational program.
Commercial Viability: How NeOnc will address development costs, financing needs, and eventual commercial economics as it progresses toward potential approval.